Published in Cancer Res on February 22, 2011
The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. Oncogene (2012) 1.11
Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge. Cancer Lett (2012) 1.00
Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein. PLoS One (2013) 1.00
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion. Front Pharmacol (2014) 1.00
Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer. Adv Drug Deliv Rev (2014) 1.00
The role of drug transporters in the kidney: lessons from tenofovir. Front Pharmacol (2014) 0.91
Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives. Int J Nanomedicine (2012) 0.90
Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets. Front Pharmacol (2015) 0.84
Pharmacological reversal of histone methylation presensitizes pancreatic cancer cells to nucleoside drugs: in vitro optimization and novel nanoparticle delivery studies. PLoS One (2013) 0.83
Concentrative nucleoside transporter 1 (hCNT1) promotes phenotypic changes relevant to tumor biology in a translocation-independent manner. Cell Death Dis (2013) 0.81
Structural basis of nucleoside and nucleoside drug selectivity by concentrative nucleoside transporters. Elife (2014) 0.81
Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition. Clin Cancer Res (2014) 0.81
Molecular Imaging of Membrane Transporters' Activity in Cancer: a Picture is Worth a Thousand Tubes. AAPS J (2015) 0.79
Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach. Cancer Lett (2015) 0.79
Predictive modeling of in vivo response to gemcitabine in pancreatic cancer. PLoS Comput Biol (2013) 0.79
PharmGKB summary: gemcitabine pathway. Pharmacogenet Genomics (2014) 0.78
Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors. Br J Pharmacol (2014) 0.77
Lipocalin-2 is associated with a good prognosis and reversing epithelial-to-mesenchymal transition in pancreatic cancer. World J Surg (2013) 0.77
Integrative genome-wide analysis of the determinants of RNA splicing in kidney renal clear cell carcinoma. Pac Symp Biocomput (2015) 0.75
Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine. Front Pharmacol (2017) 0.75
Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2. Mol Cancer (2017) 0.75
Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma. Br J Cancer (2017) 0.75
SET contributes to the epithelial-mesenchymal transition of pancreatic cancer. Oncotarget (2017) 0.75
Pancreatic cancer. N Engl J Med (2010) 13.88
Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem (2010) 12.06
BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol (2009) 11.17
The development of proteasome inhibitors as anticancer drugs. Cancer Cell (2004) 4.46
Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res (2009) 4.24
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res (2009) 4.19
MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene (2008) 4.11
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology (2008) 3.28
Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. Genes Dev (1998) 3.01
The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol Cell (2001) 2.93
Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). Cancer Res (1990) 2.39
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res (2006) 2.38
Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res (1998) 2.32
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res (2004) 2.06
Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin Cancer Res (2008) 1.82
Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res (2010) 1.69
Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res (2005) 1.64
Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res (2009) 1.62
Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol (2005) 1.61
Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity. Clin Cancer Res (2003) 1.55
Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions. Scand J Gastroenterol (2009) 1.53
Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst (1999) 1.27
Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev (2009) 1.27
Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res (2000) 1.20
Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J Gastroenterol (2010) 1.20
E- and N-cadherin differ with respect to their associated p120ctn isoforms and their ability to suppress invasive growth in pancreatic cancer cells. Oncogene (2004) 1.14
S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res (2001) 1.13
Thymidine kinase, deoxycytidine kinase and deoxycytidylate deaminase activities in phytohaemagglutinin stimulated human lymphocytes. Exp Cell Res (1971) 1.13
In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta. Am J Physiol Regul Integr Comp Physiol (2007) 1.12
New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine. Mol Cancer Ther (2008) 1.11
The role of cell cycle progression in radiosensitization by 2',2'-difluoro-2'-deoxycytidine. Cancer Res (2000) 1.02
Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes. Am J Physiol Gastrointest Liver Physiol (2008) 1.00
Macrophages require different nucleoside transport systems for proliferation and activation. FASEB J (2001) 0.98
Subcellular distribution and membrane topology of the mammalian concentrative Na+-nucleoside cotransporter rCNT1. J Biol Chem (2001) 0.95
SNAIL induces epithelial-to-mesenchymal transition in a human pancreatic cancer cell line (BxPC3) and promotes distant metastasis and invasiveness in vivo. Exp Mol Pathol (2010) 0.93
Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer. J Surg Res (2003) 0.92
Interferon-gamma regulates nucleoside transport systems in macrophages through signal transduction and activator of transduction factor 1 (STAT1)-dependent and -independent signalling pathways. Biochem J (2003) 0.90
Transport of nucleoside analogs across the plasma membrane: a clue to understanding drug-induced cytotoxicity. Curr Drug Metab (2009) 0.90
Electrophysiological characterization and modeling of the structure activity relationship of the human concentrative nucleoside transporter 3 (hCNT3). Mol Pharmacol (2006) 0.89
Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int J Cancer (2004) 0.89
Long term endocrine regulation of nucleoside transporters in rat intestinal epithelial cells. J Gen Physiol (2004) 0.85
Electrogenic uptake of nucleosides and nucleoside-derived drugs by the human nucleoside transporter 1 (hCNT1) expressed in Xenopus laevis oocytes. FEBS Lett (2000) 0.85
Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer. Oncology (2006) 0.82
Cell-cycle-dependent regulation of CNT1, a concentrative nucleoside transporter involved in the uptake of cell-cycle-dependent nucleoside-derived anticancer drugs. Biochem Biophys Res Commun (2002) 0.81
Hepatocyte nuclear factor-4alpha and bile acids regulate human concentrative nucleoside transporter-1 gene expression. Am J Physiol Gastrointest Liver Physiol (2009) 0.80
Leukapheresis induced changes in cell cycle distribution and nucleoside transporters in patients with untreated acute myeloid leukemia. Leukemia (1991) 0.79
TGF-beta transcriptionally activates the gene encoding the high-affinity adenosine transporter CNT2 in rat liver parenchymal cells. Cell Mol Life Sci (2006) 0.78
Deoxycytidine kinase and cytosine nucleoside deaminase activities in synchronized cultures of normal rat kidney cells. Cancer Res (1978) 0.77
Cancer--an ayurvedic perspective. Pharmacol Res (2005) 2.03
Profiling gene expression in human placentae of different gestational ages: an OPRU Network and UW SCOR Study. Reprod Sci (2008) 1.25
New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine. Mol Cancer Ther (2008) 1.11
Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge. Cancer Lett (2012) 1.00
Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein. PLoS One (2013) 1.00
The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes. J Pharmacol Exp Ther (2009) 0.97
Human equilibrative nucleoside transporter-3 (hENT3) spectrum disorder mutations impair nucleoside transport, protein localization, and stability. J Biol Chem (2010) 0.94
Up-regulation of vitamin B1 homeostasis genes in breast cancer. J Nutr Biochem (2013) 0.89
Transcriptional suppression, DNA methylation, and histone deacetylation of the regulator of G-protein signaling 10 (RGS10) gene in ovarian cancer cells. PLoS One (2013) 0.86
A mild form of SLC29A3 disorder: a frameshift deletion leads to the paradoxical translation of an otherwise noncoding mRNA splice variant. PLoS One (2012) 0.85
The role of nucleoside transporters in the erythrocyte disposition and oral absorption of ribavirin in the wild-type and equilibrative nucleoside transporter 1-/- mice. J Pharmacol Exp Ther (2009) 0.84
Pharmacological reversal of histone methylation presensitizes pancreatic cancer cells to nucleoside drugs: in vitro optimization and novel nanoparticle delivery studies. PLoS One (2013) 0.83
Characterization of a new antibody raised against the NH2 terminus of P-glycoprotein. Clin Cancer Res (2005) 0.80
2'-Fluoro-6'-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: in vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action. Bioorg Med Chem Lett (2012) 0.78
Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. Bioorg Med Chem Lett (2011) 0.77
Poster 280 ALS Masked by Breast Cancer History and Low Back Pain: A Case Report. PM R (2016) 0.75
Ayurvedic drug discovery. Expert Opin Drug Discov (2007) 0.75
Poster 451 Schwannoma Presenting as Low Back Pain and Myelopathy: A Case Report. PM R (2016) 0.75